Swift Biosciences is a biotechnology company that is developing novel molecular biology technologies to better characterize and understand the genome. We are an energetic, highly innovative company focused on creating tools to advance the DNA sequencing sciences. Our products are designed to help customers analyze challenging samples that are often associated with translational work, including circulating, cell-free DNA and formalin-fixed, paraffin-embedded samples.
Swift's innovative team of scientists and executives have a strong track record of joining discovery with function to make new applications and markets. Our product development is purposeful and focused on creating products that are well-regarded by both customers and their intended industries. The mission of Swift is to provide long term improvements in the health of individuals and their communities all around the world, specifically in the fight against cancer and understanding the complexities of inherited diseases. The tools developed in our efforts are directly applicable to research in agrigenomics, biotechnology, metagenomics, and the pharmaceutical industry.
Swift Biosciences entered the Next-Generation Sequencing Market in 2013 and enjoys the collaboration of renowned scientists with a history of successful businesses and the support of experienced life science investors. Our innovation pipeline, developed by our growing team of talented scientists, has generated multiple validated products for translational research across the genomics landscape and we are looking forward to adding new technologies and products to our portfolio.